Quick answer
What is Octreotide?
Built from index records dated 2026-10-09 to 2026-10-13 Compiled by an automated pipeline, checked by The Peptide Observer editorial desk. No qualified clinical reviewer. How this site works
Octreotide is a peptide, grouped on this site under Endocrine and immune signalling peptides, and the 12 research records kept here are 11 from trials in people and 1 that does not state what kind of study it is.
The literature search returned 9,618 records. This site keeps 12 of them, which is 0.12 per cent of what came back.
What it is
This site puts it in the Endocrine and immune signalling peptides group.
A somatostatin receptor agonist octapeptide; the retrieved records use its receptor binding both for secretory inhibition and, radiolabelled, for receptor imaging and radionuclide therapy.[1, 2]
Stated in the titles of the cited 1996 New England Journal of Medicine and 1993 European Journal of Nuclear Medicine papers.
What kind of records
Several of the records kept here are trials in people.
That sentence is produced by counting, not by reading. What was counted: 11 of 12 indexed records are interventional human trials by their own assigned publication type.
What this does not settle
- What it does in a body. Counting records is not reading them, and nothing here has been read in full.
- Whether it causes harm. No adverse-effect row was taken from any source for this entry.
- How long it lasts. No pharmacokinetics source was retrieved for this entry.
- What the other 9,606 retrieved records say. They are not in this index.
The longer explanation
Where this comes from
The records cited above, in full.
- Octreotide. The New England journal of medicine (1996). pmid:8532003
- Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. European journal of nuclear medicine (1993). pmid:8404961